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Bdnf exon-IV and exon-VI transcripts are driven by neuronal activity and are involved in
pathologies related to sleep, fear or memory disorders. However, how their differential
transcription translates activity changes into long-lasting network changes is elusive.
Aiming to trace specifically the network controlled by exon-IV and -VI derived BDNF
during activity-dependent plasticity changes, we generated a transgenic reporter mouse
for BDNF-live-exon-visualization (BLEV ), in which expression of Bdnf exon-IV and -VI
can be visualized by co-expression of CFP and YFP. CFP and YFP expression was
differentially activated and targeted in cell lines, primary cultures and BLEV reporter mice
without interfering with BDNF protein synthesis. CFP and YFP expression, moreover,
overlapped with BDNF protein expression in defined hippocampal neuronal, glial and
vascular locations in vivo. So far, activity-dependent BDNF cannot be explicitly monitored
independent of basal BDNF levels. The BLEV reporter mouse therefore provides a new
model, which can be used to test whether stimulus-induced activity-dependent changes
in BDNF expression are instrumental for long-lasting plasticity modifications.
Keywords: BDNF detection, Bdnf exon-IV and -VI, transgenic BDNF reporter mice, activity-dependent BDNF
expression, long-lasting plasticity changes
INTRODUCTION
Brain derived neurotrophic factor (BDNF), identified and purified in 1982 (Barde et al.,
1982), is a key modulator of synaptic function during homeostatic readjustment processes
and a master regulator of energy homeostasis (for review see: Bramham and Messaoudi,
2005; Rauskolb et al., 2010). Despite its importance, the influence of BDNF on circuit
stabilization in the adult system, or its complex role in numerous brain and cardio-vascular
diseases (Kuipers and Bramham, 2006; Marosi and Mattson, 2014; Leal et al., 2017), is still
not completely understood (Nahmani and Turrigiano, 2014). Several factors impede detailed
analysis. On the one hand, expression of BDNF in the mature CNS is extremely low and not
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restricted to neurons (Danzer and McNamara, 2004; Dieni et al.,
2012), but also found in platelets (Chacón-Fernández et al., 2016),
capillary endothelial cells (Donovan et al., 2000), microglia,
and astrocytes (Ferrini and De Koninck, 2013; Parkhurst et al.,
2013). Most enigmatic, however, is the complex structure of
the BDNF gene, which consists of eight non-coding exons
(I-VIII), which are alternatively spliced to the protein-encoding
exon-IX. Transcription of each of the resulting mRNAs is
regulated differently in terms of temporal and spatial location,
additionally some transcripts show stimulus- and activity-
dependence (Pattabiraman et al., 2005; Chiaruttini et al., 2008).
The resulting transcripts in turn display different stability,
targeting, and translatability (Timmusk et al., 1993; West et al.,
2014). Ultimately, each transcript is translated into an identical
BDNF peptide, cleaved and released as mature BDNF (Yang et al.,
2009). BDNF transcripts containing Bdnf exon-IV and -VI are
particularly interesting as their translation is directly or indirectly
regulated by changes in neuronal activity (Hong et al., 2008;West
et al., 2014; Tuvikene et al., 2016) and their dysregulation is linked
to various brain pathologies related to sleep, loss of fear memory
(Hill et al., 2016), and depression (Marosi and Mattson, 2014).
BDNF-TrkB receptor signaling is crucial for activity-dependent
regulation of synaptic strength in various brain regions (Kellner
et al., 2014). Moreover, activity-dependent regulation of synaptic
strength was previously suggested to play a role during long-
lasting adaptation of brain responses to external demand.
Accordingly, only the coincidence of for example glucocorticoid
function acting on mitochondria and dendritic spines together
with context-specific activity (e.g., motor learning), lead to long-
lasting spine formation, memory consolidation and behavioral
performance (see for a review: Jeanneteau and Arango-Lievano,
2016). In this context the potential function of activity-dependent
BDNF to provide context information cannot be tested due
to difficulties in its detection in the adult organ (Dieni et al.,
2012), and unfeasibility to extract activity-dependent BDNF from
background BDNF levels.
To investigate whether activity-dependent Bdnf exon-IV
or -VI promoter usage provides context-specific information
during task-specific learning, we generated a knock-in reporter
mouse line for BDNF-live-exon-visualization (BLEV). In contrast
to previous studies analyzing the distinct functions of Bdnf
transcripts through deletion of promoter function (Hong et al.,
2008; Sakata et al., 2010; Parkhurst et al., 2013; Mallei et al.,
2015), we generated a BDNF knock-in reporter mouse. In the
BLEV reporter mouse line, the marker proteins CFP and YFP
(cyan- and yellow-fluorescent protein) tag the sites, wheremRNA
containing the activity-dependent Bdnf exon-IV or exon-VI
is translated. This allows monitoring of exon-IV and exon-VI
promoter usage in vitro and in vivo above the background of
basal BDNF levels. We verify that the knock-in does not interfere
with the normal BDNF transcription, translation or protein
function and approve the specific detection of activity-driven
BDNF transcript changes in the brain.
The BLEV reporter mouse thus constitutes the first model to
allow selective and sensitive tracing of activity-dependent Bdnf
transcripts in functional neuronal networks in vitro and in vivo,
without impairing normal BDNF protein functions.
MATERIALS AND METHODS
Animals
Animal care and use and experimental protocols correspond
to national and institutional guidelines and were reviewed
and approved by the animal welfare commissioner and the
regional board for animal experimentation. All experiments
were performed according to the European Union Directive
2010/63/EU for the protection of animals used for experimental
and other scientific purposes.
Vector Construct for a Transgenic BDNF
Mouse
The Bdnf exon-IV sequence is extended by CFP and the Bdnf
exon-VI sequence by YFP, both containing a stop codon. The
translation of Bdnf exon-IX is enabled by an IRES sequence,
which keeps the mRNA at the ribosome, despite the presence
of a stop codon. Additionally, the growth-associated protein 43
(GAP43), is added to anchor the fluorescent proteins at the site of
translation. This allows differential monitoring of the non-coding
Bdnf exon-IV and Bdnf exon-VI by the fluorescent proteins CFP
and YFP without interfering with Bdnf exon-IX.
In detail, to generate a mouse line in which different Bdnf
exons are labeled by different fluorescent markers (Figure 1A),
Bdnf exon-IV and -VI were amplified from genomic DNA.
Primers were designed to amplify Bdnf exon-IV (5′-TAGAA
CCTTGGGGACCATGCTGTGCTGTATGAG-3′, 5′-CAGCA
CAGCATGGTCCCCAAGGTTCTAGACTC-3′; 5′-GAGAA
AGCGCAGGGACCATGCTGTGCTGTGCTGTATGAG-3′;
5′-CAGCACAGCATGGTCCGTGCGCTTTCTCTGCTGC
C-3′) or Bdnf exon-VI (5′-GTGGGGCAAAGCGAACTGTG
A-3′, 5′-CGCAACCCCCATAACGACCAG-3′) including their
promoter regions. The PCR product was digested with the
enzymes XhoI, SbfI, and MluI for exon-IV and XhoI, AccIII,
and MluI for exon-VI to separate the two exons. In a next step,
oligonucleotides specific for the membrane anchoring sequence
of GAP43, the hemagglutinin (HA) epitope tag, and cMyc
(cellular myelocytomatosis oncogene) epitope tag were designed.
GAP43 was cloned into the 5′-multiple cloning site (MCS) of the
CFP and the YFP vectors (Takara Bio Europe/Clontech; https://
www.takarabio.com/assets/documents/Vector%20Documents/
pAmCyan%20Vector%20Information.pdf, https://www.
takarabio.com/assets/documents/Vector%20Documents/
PT3481-5_080612.pdf). The HA tag was inserted into the
3′-MCS of the CFP vector, and the cMyc tag was inserted into
the 3′-MCS of the YFP vector. A chimera of Bdnf exon-IV and
the CFP vector containing GAP43 and HA was amplified. The
same was done for Bdnf exon-VI and the YFP vector containing
GAP43 and cMyc. To make use of an internal ribosomal entry
site (IRES), the two PCR products were cloned into a pIRES
vector (Takara Bio Europe/Clontech, http://www.takara.co.kr/
file/manual/pdf/PT3266-5.pdf). The PCR product containing
Bdnf exon-IV, GAP43, CFP, and HA was inserted into the MCS
A of the pIRES vector. The same was done for the PCR product
containing Bdnf exon-VI, GAP43, YFP, and cMyc. To design
a construct containing Bdnf exon-IV and -VI in one vector,
Bdnf exon-VI, GAP43, YFP, cMyc, and pIRES were cut out
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FIGURE 1 | BLEV construct and verification of the in vitro. (A) Schematic drawing of the Bdnf exon-IV-CFP and Bdnf exon-VI-YFP single constructs used in cell
culture. (B) Schematic drawing of the Bdnf exon-IV-CFP and exon-VI-YFP double construct used in cell culture. (C,D) CFP expression of the Bdnf exon-IV-CFP single
construct (blue, left panel, nuclear staining: propidium iodide, in red) and YFP expression of the Bdnf exon-VI-YFP single construct (yellow, right panel, nuclear
staining: DAPI, in blue). (E) ELISA of BDNF protein in SK-N-BE cells transfected with either the Bdnf exon-IV-CFP single construct or the Bdnf exon-VI-YFP single
construct. BDNF is not expressed in cells treated with Lipofectamine (LTX, gray bar) only. BDNF is expressed in SK-N-BE cells transfected with either of the two single
constructs (blue bar: Bdnf exon-IV-CFP; yellow bar: Bdnf exon-VI-YFP). Data are shown as mean BDNF concentration (pg/ml) ± SEM [1-way ANOVA: F (3,36) = 8.35
p = 0.0002; post-test 2-sided Student’s t-test: CFP p = 0.008; YFP p = 0.003; done in duplicate for 4 independent experiments]. (F) SK-N-BE cells transfected with
the Bdnf exon-IV-CFP exon-VI-YFP double construct. The left panel shows the CFP expression (blue), the middle panel shows the YFP expression (yellow), and the
right panel shows a merged image of Bdnf exon-IV-CFP and Bdnf exon-VI-YFP expression. Open arrows show cells expressing either CFP or YFP, filled arrows show
cells expressing CFP and YFP. Nuclear staining in red (propidium iodide). (C,D) scale bars = 20µm; (F) scale bar = 50µm.
of one pIRES vector and cloned into the MCS B of the pIRES
vector, which already contained Bdnf exon-IV, GAP43, CFP, and
HA. From this pIRES vector, the part containing Bdnf exon-IV,
GAP43, CFP, HA, pIRES and Bdnf exon-VI, GAP43, YFP,
cMyc, pIRES were inserted together with the loxP sites of the
pMCS 5 vector (http://www.mobitec.com/cms/products/bio/04_
vector_sys/multiple_cloning_site_pmcs5.html, kindly provided
by Prof. Dusan Bartsch; Central Institute of Mental Health,
Department of Molecular Biology, Mannheim, Germany), into
the pEasyFloxII/SK62 vector between the neomycin cassette
and the HSV-TK cassette. The 5′-homologous sequence was
also inserted into the pEasyFloxII/SK62 vector in front of the
neomycin cassette. This vector construct was used to generate
the transgenic mouse line.
Generation of the Transgenic BDNF Mouse
The construct was linearized with NotI and electroporated
into HM1 embryonic stem (ES) cells (Magin et al., 1992).
ES cell clones were selected with neomycin. Recombinant ES
cell clones were verified by PCR using oligonucleotides for
the 5′-end (for: 5′-GAGTTGGGAGAATATTAGGC-3′; rev:
AGGTAGCCGGATCAAGCGTATGCAGC-3′) and the 3′-end
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(for: 5′-GTCCTGCTGGATATATACATGGGGCAG-3′; rev:
5′-GTCAACTTATAATTACCGGTTCC-3′) resulting in PCR
products of either 2.5 or 6.7 kb, respectively. Positive clones were
screened additionally by Southern blot. In brief, isolated DNA
was digested using EcoRV and SalI (Roche). DNA fragments
were separated on a 0.8% agarose gel. The DNA was blotted
onto a nylon membrane and fixed. Different DNA probes were
hybridized to the membrane at 68◦C overnight. On the next
day, bands were visualized using the detection starter Kit II
(Roche). The probes were specific either for the 5′-end, the
3′-end and two internal sequences, covering either parts of the
transgenic exon-IV or -VI. Due to the restriction sites, the WT
and the transgenic allele could be differentiated. For the 5′-end
probe, the WT band was 9.8 kb, the band of the transgenic
allele was 3 kb; for the 3′-end, the WT and the transgenic band
was 12.7 kb. For the probe covering exon-IV, a WT band of
9.8 and 5.3 kb band for the transgenic allele were obtained.
The probe covering exon-VI resulted in a 9.8 kb band for the
WT and a 6.3 kb band for the transgenic allele (Figure 3C,
Supplementary Figure 1). A selected ES cell clone was used for
injection into blastocysts. Chimeras were carried out by foster
mothers. Deletion of the Neo cassette was achieved by breeding
the offspring with Pgk-Cre mice (Lallemand et al., 1998).
Genotyping of these mice was performed using oligonucleotides
for Cre (for: 5′-ACGACCAAGTGACAGCAATA-3′, rev: 5′-
CCATGCCTCGACCAGTTTAG-3′). For genotyping the
transgenic BDNF mouse, two primer sets were used. The
insert PCR of CFP (for: 5′-GAACAGGAGTACATATCGGCC-
3′, rev: 5′-TTCATATGACATTCCGTCAGG-3′) resulted in
a 437 bp PCR product for the transgenic mouse and no
PCR product for the WT. To verify the different genotypes,
additional PCRs were performed using the forward primer 5′-
GAACAGGAGTACATATCGGCC-3′ and either the reverse
primer 5′-GAACACACAATGAAACTACACAGAG-3′ for the
WT resulting in a 428 bp product, or 5′-TTCATATGACA
TTCCGTCAGG-3′ for the transgene (437 bp). The BLEV
mouse line (B6;129-Bdnftm1(ex4CFPex6YFP)MknixB6;HM1-
Pgktm1(Cre)Lni/Mkni) was maintained by breeding
heterozygotes.
CELL CULTURE
Vector Construct for Cell Culture
For the constructs used in cell culture, Bdnf exon-IX was
inserted in the MCS B of the pIRES vectors containing either
Bdnf exon-IV, GAP43, CFP, and HA, or Bdnf exon-VI, GAP43,
YFP, and cMyc (single constructs, Figure 1A). To receive the
double construct, Bdnf exon-IX was cut out of the pIRES vector
containing Bdnf exon-IV, GAP43, CFP, and HA. Instead, the
vector part Bdnf exon-VI, GAP43, YFP, cMyc, and Bdnf exon-
IX from the single construct was inserted into the MCS B
(Figure 1B).
Cell Culture and Transfection
SK-N-BE cells, kindly provided by PD Dr. Ulrike Naumann
(Hertie Institute, Tübingen, Germany), were grown on 75 cm2
flasks in 11ml Dulbecco’s Modified Eagle’s Medium (DMEM)
(Gibco/Life Technologies) containing 10% fetal calf serum
(Gibco/Life Technologies) and 1% penicillin and streptomycin
(Gibco/Life Technologies). Cells were sub-cultured for 2 days
at 3 × 104 cells/well (BD Bioscience), ensuring cells would be
in the log phase of differentiation. The cells were transfected
with two different BDNF single constructs or the double
construct (Figures 1A–D) when they were 50–80% confluent
using the lipid-based transfection reagent LTX (Lipofectamine,
Life Technologies) according to manufacturer’s guidelines. For
each DNA construct, 3.5 µg of DNA was gently diluted in 700
µl of DMEM together with 3.5 µl of plus reagent and 7 µl of LTX
and incubated for 25-30min at room temperature. DNA/LTX
solution (about 700 µl) and 1,300 µl of serum-free medium were
added to each well and mixed by gently rocking the plate for 5 h.
The culture medium was changed to standard medium and the
cells were incubated at 37◦C, 5% CO2 for 24 h.
ELISA (Enzyme-Linked Immunosorbent
Assay) for BDNF
For SK-N-BE cells transfected with 1.5 µg of either single
construct (Figure 1A) or treated with Lipofectamine only, ELISA
for BDNF protein was performed using the ELISA kit from
Chemicon. BDNF content was determined from A450 readings
of human BDNF standards.
Primary Neuronal Culture
Primary mixed neuronal cultures of cortical neurons (mice
postnatal day P1-7) or hippocampus (rat, embryonic day E17-18)
were prepared following the procedure described by Goslin et al.
(1998) and Salazar et al. (2017).
For transfection, primary cortical neurons were plated 7–11
days and transfected with 1–2 µg of the double construct Bdnf
exon-IV-(HA)-CFP/Bdnf exon-VI-(cMyc)-YFP-exon-IX and 1–
2 µl Lipofectamine 2000 (Life Technologies) solution (1 mg/ml)
diluted in 50–80 µl MEM without serum and antibiotics.
The Lipofectamine 2000 and DNA mix was removed 1 h after
transfection. The cells were returned to the initial conditioned
medium and were incubated in a 5% CO2-humidified incubator
at 37◦C for 7 d to allow the expression of transfected constructs.
Stimulation of Hippocampal Primary
Culture With Bicuculline
Hippocampal neurons transfected at 7 DIV were stimulated
at 15 DIV with 50µM bicuculline, 2.5mM 4-Aminopyridine
and 10µM glycine for 3 h as previously described (Costa et al.,
2016). They were fixed for 15min at RT in 4% paraformaldehyde
in PBS and mounted in fluorescence mounting medium
(DAKO). Fluorescence was analyzed with a Nikon C1Si confocal
microscope (Nikon Instruments Europe BV, Amsterdam,
Netherlands). A series of optical images at 0.2µm increments
along the “z” axis of the cells stained was acquired. Images
were processed for z-projection and for illustration purposes
by using ImageJ (NIH, Bethesda, USA) and Adobe Photoshop
CS4 (Adobe Systems, San Jose, CA). For immunohistochemistry
(Supplementary Figure 2) hippocampal neurons were fixed as
described above. They were permeabilized with 0.3% Triton
X-100 in PBS and incubated with 10% BSA in PBS, for 30min
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at 37◦C, to block non-specific staining. Afterwards they were
incubated for 2 h at 37◦C with the primary antibodies against HA
(-CFP) and cMyc (-YFP) diluted in 3% BSA in PBS, for antibody
information see Supplementary Table 1. The cells were washed
6 times with PBS for 2min and incubated with the secondary
antibodies (see Supplementary Table 1), for 45min at 37◦C.
Afterwards the coverslips were mounted with a fluorescence
mounting medium (DAKO). Here fluorescence images were
acquired using a Carl Zeiss LSM 710 confocal microscope
with a Plan-Apochromat 63×/1.4 objective using identical
settings, with the following excitation lasers/wavelengths:
DPSS 561-10/561nm [Red; to visualize Bdnf exon-IV-(HA)-
CFP], and HeNe633/633nm [Far-Red; to visualize Bdnf
exon-VI-(cMyc)-YFP].
Kainic Acid Injection
Two to three-month-old homozygous BLEV mice of either
sex were injected intraperitoneally with 12mg/kg kainic acid
(Tocris) (KA). This concentration has been previously shown to
induce an activity-dependent expression of Bdnf exon-IV and -
VI in the hippocampus (Chiaruttini et al., 2008). Control animals
received the same amount of 0.9% NaCl solution (Fresenius)
(vehicle-treated animals). Two hours after injection animals were
sacrificed. Animals developed hardly any seizures as they were
generated on a C57BL/6N background, which was shown to be
resistant to KA-induced insults (Mclin and Steward, 2006).
Hearing Measurements
The hearing function of 2–3 months old homozygous BLEV
mice of both sexes was studied by measuring auditory brainstem
responses (ABRs), as described previously (Zuccotti et al., 2012;
Rüttiger et al., 2013).
Tissue Preparation
For RNA and protein isolation, brains were dissected with
small forceps and immediately frozen in liquid nitrogen and
stored at −80◦C before use. Brain and cochlear tissue for
immunohistochemistry was prepared as previously described
(Singer et al., 2016).
RNA Isolation
RNA was extracted from brain tissues with a ready-to-use kit
according to the manufacturer’s protocol (Macherey-Nagel).
Semi-quantitative Reverse Transcription
and Polymerase Chain Reaction (RT-PCR)
Transcription of RNA to cDNA was carried out as previously
described (Tan et al., 2007). Transcribed cDNA was amplified
using PuReTaq Ready-To-Go PCR beads (Amersham
Biosciences). Specific forward- and reverse primers for
Bdnf exon-IX (for: 5′-GAAGCAAACGTCCACGGACAA-
3′, rev: 5′-CTGGATGAGGACCAGAAGGTT-3′, 171 bp)
were used. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH, for: 5’-TCTACTGGTGTCTTCACCACCA-3′,
rev: 5′-ACTGAGGACCAGGTTGTCTCCT-3′, 600 bp) was used
as housekeeping gene. Primers for Bdnf exons I, II, III, IV, V,
VI, VII, VIII and XIA were used according to (Aid et al., 2007).
A probe containing the same reagents except the cDNA was
used as a negative control. The resulting PCR products were
separated on 1.5% agarose gels by electrophoresis and stained
with ethidium bromide.
Protein Isolation and Western Blot
For isolation of cMyc-tagged proteins and HA-tagged proteins,
the Mild Purification kit and the HA-tagged Protein Purification
kit were used, respectively (BiozolDiagnostica). In brief, tissues
were dissolved in a lysis buffer (CelLytic M, Sigma-Aldrich)
and incubated for 1 h with anti-cMyc or anti-HA tag beads
suspension. The suspension was then centrifuged and washed;
cMyc- and HA-tagged proteins were eluted with Elution Peptide
Solution from the kit.
For BDNF Western blot, co-immunoprecipitation was
performed using the Catch and Release v2.0 (Merck Millipore).
In brief, tissues were dissolved in lysis buffer (CelLytic M). After
preparing the columns with Catch and Release wash buffer, tissue
lysate, antibody (anti-BDNF, Genaxxon Bioscience), antibody
capture affinity ligand and wash buffer were added to the column.
Loaded columns were incubated overnight at a mixer at room
temperature. On the next day, the column was centrifuged and
washed followed by the elution of the proteins.
Proteins were separated by electrophoresis and placed on a
transfer membrane; non-specific epitopes of the membrane were
blocked with 5% milk powder solution and incubated overnight
at 4◦C with the primary antibody (see Supplementary Table 1).
On the second day, the membrane was washed three times with
Tris buffer/0.1% Tween 20; the secondary antibody (HRP-linked
ECL anti-rabbit IgG or HRP-linked ECL anti-mouse IgG; GE
Healthcare) was incubated for 1 h at room temperature in a sealed
envelope. The membrane was washed again three times with Tris
buffer/0.1% Tween 20. Finally, the protein bands were visualized
with ECL Prime WB Detection Reagent (GE Healthcare) using
the Proxima 2700 (Isogen Life Science).
Immunohistochemistry
Brain tissue were isolated, fixed, sectioned, and stained as
previously described (Tan et al., 2007; Singer et al., 2016). For
antibody information see Supplementary Table 1.
DATA ANALYSES
Statistics
All Statistical results and information can be found in the figure
legends and in Supplementary Table 2. In figures, significance
is indicated by asterisks (∗p < 0.05, ∗∗p < 0.01). For animal
experiments Power analyses is performed a priori for the
applications for animal experiments. A sample size of 4-5
animals per group is sufficient to evaluate a difference in hearing
threshold of 10 – 15 dB SPL (alpha 0.05, Power 0.8). For
molecular analyses a sample size of 3 – 4 is sufficient to evaluate a
difference in gene/protein expression of 15% (alpha 0.05, Power
0.8). For analyses of hearing thresholds no data were excluded,
in all mice a hearing threshold could be measured. Molecular
samples were excluded when the standard curves were not fitting
(ELISA), bands were missing or the housekeeping genes in PCR
or Western Blot were irregularly expressed.
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ELISA
Data are shown as mean BDNF protein concentration in (pg/ml)
(± SEM). Data were statistically analyzed by Student’s t-test with
α= 0.05.
PCR
The intensity of the bands was analyzed using the TotalLab
Quant software (TotalLab Ltd.). Band intensities of BDNF were
normalized to housekeeping gene GAPDH. Results are depicted
in relation to Bdnf exon-IX expression of WT mice, which was
set to 1 (dotted line) as mean ± % SEM. Data were analyzed
by 1-way ANOVA with α = 0.05, post-test: Bonferroni-Holms
(GraphPad Prism). For the untranslated Bdnf exons I, II, III,
IV, VI, and XIA mean expression values ± SEM are shown for
WT and homozygous mice. Data were analyzed for each exon
by 2-sided Student’s t-test with α = 0.05 (GraphPad Prism). For
original picture see Supplementary Figure 6D.
Western Blot
The intensity of the bands was analyzed using the TotalLab
Quant software. Band intensities of the genes of interest were
normalized to housekeeping gene GAPDH. For BDNF results are
depicted in relation to BDNF expression of WT mice, which was
set to 1 (dotted line) as mean ± % SEM. Data were analyzed by
1-way ANOVA with α = 0.05, post-test: Bonferroni-Holms. For
tissue from kainic acid-treated mice, results are shown as % of
vehicle-treated mice as mean ± % SEM. Data were analyzed by
a 1-sided Student’s t-test with α = 0.05 (GraphPad Prism). For
original Blots see Supplementary Figures 6B,C.
Hearing Measurements
Click-ABR measurements were analyzed by 1-way ANOVA
with α = 0.05, post-test: Bonferroni-Holms. Frequency-ABR
measurements were group analyzed by multiple t-test with α =
0.05, corrected for multiple comparison using the Holm-Sidak
method (GraphPad Prism). Data are shown as mean± SD.
Fluorescence Analysis of Brain
Immunohistochemistry
Sections shown here were viewed using an Olympus BX61
microscope (Olympus, Center Valley, PA, USA) equipped with
an X-Cite Lamp (Olympus). Images were acquired using an
Olympus XM10 CCD monochrome camera and analyzed with
cellSens Dimension software (OSIS).
To increase spatial resolution, slices were imaged over a
distance of 13–15µm in steps of 0.49µm within an image-
stack along the z-axis (z-stack) followed by 3-dimensional
deconvolution, using a cellSens Dimension built-in algorithm.
Typically z-stacks consisted of 27–30 layers, for each layer one
image was acquired per fluorochrome.
Picture acquired from brain section stained for parvalbumin
(PV), were analyzed using the free software ImageJ. (NIH,
Bethesda, MD, USA). For each section, three pictures for
each single channel (YFP, CFP, PV) were saved and analyzed
independently.
For integrated density analysis following vehicle and kainic
acid treatment, images from equivalent CA3 regions between
treatments were analyzed with ImageJ software to quantify
integrated density of CFP and YFP staining within each image
for each replicate. Threshold adjustments were set to ensure
quantification of only positive immunostaining.
Data Availability
The datasets generated during and/or analyzed during the
current study are available from the corresponding author upon
request.
RESULTS
Generation of a Transgene to Monitor
Transcript IV- and Transcript VI-Specific
BDNF Synthesis
In order to generate a system to monitor the sites of transcript-
specific BDNF synthesis subsequent to activity-dependent
activation of exon-IV or exon-VI promoters in vivo, we generated
constructs, which allow BDNF-live-exon-visualization (BLEV)
(Figure 1). In the BLEV constructs Bdnf exons-IV and -VI are
labeled by two different fluorescence proteins: the Bdnf exon-IV
sequence is extended by CFP and the Bdnf exon-VI sequence
by YFP, both containing a stop codon. To retain translation
of the coding Bdnf exon-IX, we introduced an IRES (internal
ribosome entry site) sequence, which keeps the mRNA at the
ribosome, despite the presence of a stop codon within CFP
or YFP. Additionally, the fluorescent proteins were fused to
the membrane tag GAP43, in order to anchor them at the
site of translation. This design allows localization of when
and where Bdnf exon-IV and -VI mRNA is used by CFP
and YFP fluorescence without interrupting post-translational
processing of BDNF (Figures 1A,B). Two different epitope tags
(HA, cMyc) were incorporated into the construct to facilitate the
quantification of CFP or YFP expression by e.g., Western blot
(Figures 1A,B). Thus, the design of these constructs allows for
the quantification of the amount of transcript specific mRNA
used for protein translation.
The feasibility of this approach was first tested by transfecting
the neuroglioblastoma cell line SK-N-BE, with either the exon-
IV-CFP (Figures 1A upper panel, C) or the exon-VI-YFP
single construct (Figures 1A lower panel, D). Distinct SK-N-BE
cells exhibited either CFP or YFP expression (Figures 1C,D).
To confirm whether BDNF protein is synthetized from these
constructs, we performed ELISA assays to compare BDNF
protein levels between untransfected and transfected cells
(Figure 1E). Both single constructs clearly led to elevated levels
of BDNF protein expression (blue column: Bdnf exon-IV-CFP
(HA)-IX; yellow column: Bdnf exon-VI-YFP (cMyc)-IX) in
comparison to untransfected cells treated with Lipofectamine
(LTX) only (Figure 1E, gray column). The differences in
BDNF protein expression between the two single constructs
might be due to the different activation potential of the
promoter regions of Bdnf exon-IV and -VI (Baj and Tongiorgi,
2009). Furthermore, a different transfection rate of the exon-
IV-CFP and the exon-VI-YFP single constructs cannot be
excluded as the cells are not stably transfected. Next, we tested
the capacity of the double construct to visualize differential
expression of Bdnf exon-IV-CFP and Bdnf exon-VI-YFP in
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FIGURE 2 | Verification of the BLEV double construct in primary neuronal cultures. (A) Mouse primary cortical cell culture (postnatal day 2) transfected with the BDNF
double construct. Left panels: Bdnf exon-IV-CFP expression; middle panels: Bdnf exon-VI-YFP expression; right panels: merged images. Top and bottom panels
represent two different neurons. Scale bar: 20µm. (B) Transfected rat primary hippocampal neurons (embryonic day E18) without (left) or with bicuculline (right)
stimulation showing Bdnf exon-VI-YFP expression. Bdnf exon-IV-CFP expression showed an increase preferentially in the cell body (Supplementary Figure 2A,
arrows), while exon-VI-YFP was predominantly detected in proximal and distal regions of the neurites (Supplementary Figure 2B, lower panels). Scale bars: 10µm.
distinct cells (Figure 1F). Transfection of the SK-N-BE cells lead
either to the expression of CFP (Figure 1F, left panel, open
arrows), YFP (Figure 1F, middle panel, open arrows), or both
fluorescence proteins (Figure 1F, closed arrows) confirming that
parallel observation of the two non-coding exons expressed
from the double construct is feasible. When the double
construct (Figure 1B) was transfected into primary neuronal
cultures of the auditory cortex (AC) (Figure 2A), exon-IV-
CFP preferentially localized to somata, with comparably limited
targeting to dendrites (Figure 2A, upper and left panels). Exon-
VI-YFP, in contrast, was predominantly found in dendrites,
and only rarely in the soma (Figure 2A, compare upper and
lower panel). This differential distribution of exon-IV-CFP
and exon-VI-YFP suggests that the GAP43 membrane-tag
does not interfere with the visualization of the fluorescence
proteins as observed previously (Liu et al., 1994). Next,
transfected primary cultures of hippocampal neurons were
treated with theGABAA receptor antagonist bicuculline (50µM),
4-aminopyridine (2.5mM), and glycine (10µM) (Figure 2B), to
elevate spontaneous activity which upregulates BDNF expression
(Kim et al., 2012). This led to a clear increase in localization
of exon-VI-YFP in dendrites and dendritic spines (Figure 2B).
Distinct results were obtained for exon-VI-YFP and exon-IV-
CFP, with the latter construct showing following bicuculline
treatment an increased expression preferentially in the cell
body (Supplementary Figure 2A, arrows), while exon-VI-YFP
was predominantly detected in proximal and distal regions of
the neurites (Supplementary Figure 2B, lower panels). These
results confirm that in primary cultures of hippocampal
neurons BDNF derived from both exons is differentially
targeted to distinct subcellular compartments (Vaghi et al.,
2014).
In summary, we introduce a new gene construct, BLEV,
allowing observation of changes in exon-IV and exon-VI Bdnf
promoter usage in response to defined stimuli in vitro.
Generation of a Reporter Mouse Model to
Monitor Exon-IV-CFP and Exon-VI-YFP
The BLEV construct was inserted into the genomic locus of Bdnf
via homologous recombination in mouse embryonic stem cells to
replace the region harboring exon-IV, -V, -VI, and -VII (between
bp 21,000 and 30,485 GenBank ID AY057907) (Figures 3A,B).
Fidelity of the targeting event was validated by Southern blots
using internal as well as 5’ or 3’ external probes (Figure 3C). The
genomic DNA was cut by EcoRV [Figure 3C, arrows indicate
EcoRV restriction sites (RS)] for Southern blotting. The results
confirmed the correct insertion within the genomic BDNF
sequence using specific probes for the 5’-end (Probe 1, wildtype
(WT) band 9.8 kb, transgenic allele 3 kb), the exon-IV transgene
(Probe 2, WT band 9.8 kb, transgenic allele 5.3 kb), the exon-
VI transgene (Probe 3, WT band 9.8 kb, transgenic allele 6.3 kb)
and the 3’-end (Probe 4: WT and transgenic allele 12.7 kb),
respectively (Figure 3C).
Chimeras were carried by foster mothers and bred over two
generations to obtain homozygous BLEV reporter mice. All
three genotypes (WT, heterozygous and homozygous animals)
were obtained at the expected Mendelian ratio (Figure 4A),
were fertile, and had a normal life span. Also, no differences
in body weight, known to occur upon BDNF deficits (for
reviews see: (Rios, 2013, 2014) were observed between WT,
heterozygous, and homozygous mice (Figure 4B). Furthermore,
using RT-PCR (Figure 4C) and Western blot (Figure 4D), no
differences in the hippocampal levels of mRNA containing
Bdnf exon-IX, the only protein-encoding region of BDNF, or
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FIGURE 3 | Generation of the BLEV reporter mouse. (A) Schematic drawing of the Bdnf gene (Aid et al., 2007) and the BDNF vector construct used for homologous
recombination. Crossing-over events are indicated by red dotted lines and crosses. The 5’ and 3’ parts for homologous recombination are marked in red. (B) Bdnf
gene construct depicting insertion sites of the BLEV construct. Arrows indicate the EcoRV restriction sites (RS) used for Southern blot. Black arrows indicate EcoRV
RS cutting the WT and the transgenic sequence, red arrows cut only the transgenic sequence. (C) Southern blot of a positively transfected ES cell clone. The
positions of the four Southern blot probes (colored lines: green, blue, orange, and pink) are shown under the schematic drawing of the BDNF construct. Probe 1,
specific for the 5′-end: WT band 9.8 kb, transgenic allele 3 kb; probe 2, covering parts of exon-IV transgene: WT band 9.8 kb, transgenic allele 5.3 kb; probe 3,
covering parts of the exon-VI transgene: WT band 9.8 kb, transgenic allele 6.3 kb; probe 4, specific for the 3′-end: WT and transgenic allele 12.7 kb. Note that the size
of the drawn construct and probes does not reflect the real size of the DNA fragments obtained by Southern blot. For original Blots see Supplementary Figure 1.
BDNF protein between adultWT, heterozygous and homozygous
BLEV mice were detected (Figures 4C,D). No changes in the
expression of untranslated Bdnf exons (I, II, III, IV, VI, IXA)
were observed using RT-PCR (Supplementary Figure 3). The
untranslated exons V, VII, andVIII were below the detection level
of RT-PCR in the hippocampus.
Previous findings demonstrated mild but significant hearing
loss in mice with BDNF deletion in the cochlea (Zuccotti
et al., 2012). We compared threshold of ABRs of heterozygous
and homozygous BLEV mice to WT controls for click-
stimuli (Figure 4E, click-ABR) and frequency-dependent ABRs
(Figure 4E, frequency-ABR). No apparent differences between
the genotypes were observed. Additionally, BLEV mice did
also not show any circling behavior indicating impaired BDNF
expression in the vestibular system (Kaiser et al., 2001; Zuccotti
et al., 2012).
Taken together, normal BDNF levels in the CNS and the lack
of BDNF-specific phenotypes suggest that BLEV reporter mice
retain physiological BDNF expression and functionality.
Exon-IV-CFP and Exon-VI-YFP Expression
in BLEV Reporter Mice Co-localize With
Endogenous BDNF in Neuronal, Glial, and
Vascular Cells
To further validate the BLEV reporter mouse line we next
compared exon-IV-CFP and exon-VI-YFP fluorescence signals
with BDNF protein expression in vivo. These experiments were
performed in hippocampal brain slices of homozygous BLEV
reporter mice (Figures 5, 6). Hippocampal sections were stained
with an antibody specific for the BDNF pro-domain (Dieni
et al., 2012; Figures 5, 6, BDNF, see Supplementary Table 1).
BDNF staining was compared to exon-IV-CFP and exon-VI-YFP
signals in sections co-stained with markers for excitatory and
inhibitory neurons, glial cells or vascular cells and correlated to
previously described sites of BDNF expression (Figures 5, 6, see
Supplementary Table 1) (for review see: Edelmann et al., 2014).
In particular those described in distinct hippocampal cells
(Danzer and McNamara, 2004; Danzer et al., 2008).
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FIGURE 4 | Phenotype of the BLEV mouse line. (A) Heterozygous BLEV
mouse (white; left panel) and adult homozygous animals (right panel). (B)
Comparison of the weight of the different genotypes (WT; het; hom). Individual
symbols represent individual animals (WT n = 9, Het n = 11, Hom n = 11
animals). (C) Analysis of Bdnf exon-IX mRNA expression by RT-PCR in the
hippocampus of BLEV mice for WT, heterozygous and homozygous animals.
BDNF expression was normalized to the WT expression level (dotted line). No
changes in the expression of untranslated Bdnf exons (I, II, III, IV, VI, IXA) were
observed using RT-PCR (Supplementary Figure 3). Housekeeping gene:
(Continued)
FIGURE 4 | GAPDH. Data represented as mean ± SEM [1-way ANOVA: F (2,9)
= 0.15 p = 0.86; n = 3 animals/genotype]. For original picture see
Supplementary Figure 6A. (D) Analysis of BDNF protein expression by
Western Blot in the hippocampus of BLEV mice for WT, heterozygous and
homozygous animals. BDNF expression was normalized to the WT expression
level. Housekeeping gene: GAPDH. Data represented as mean ± SEM [1-way
ANOVA: F (2,12) = 0.20 p = 0.82; n = 4 animals/genotype]. For original blot
see Supplementary Figure 6B. (E) Basic hearing function of BLEV mice for
WT, heterozygous and homozygous animals. Thresholds for auditory
brainstem responses (ABR) to click-stimuli (left panel) and varying pure tone
frequencies (right panel). Data represented as mean ± SD [click-ABR: 1-way
ANOVA: F (2,26) = 1.988 p = 0.16; f-ABR: 2-way ANOVA: F (18,2665) = 0.50 p
= 0.96; WT n = 10; het n = 15; hom n = 5 animals].
Examination of BDNF signals in the dentate gyrus (DG)
at low-magnification revealed immunoreactivity (IR) in the
supra- and infra-pyramidal blades of the granule cell layer (GCL,
Figure 5A), as previously observed (Dieni et al., 2012). No
labeling was detected when the BDNF antibody was omitted
(Figure 5A, right upper panel). Under high magnification, we
detected co-localization of BDNF with a few exon-IV-CFP
positive dots in the GCL, but not with exon-VI-YFP (Figure 5A,
lower panel, arrows). Moreover, BDNF-IR was observed in at
least five different characteristic regions, as here shown for the
SR at the level of the CA1, that were either co-labeled with
exon-IV-CFP (Figure 5B, No. 1, Supplementary Figure 4),
exon-VI-YFP (Figure 5B, No. 2–4), or neither of the
fluorochromes (Figure 5B, No. 5; Supplementary Video 1,
Supplementary Figure 4). Additionally, faint BDNF-IR was
observed in blood vessels (Figure 5C) where it co-localized
with exon-IV-CFP, but not exon-VI-YFP (Figure 5C, upper
panel). No BDNF labeling was detected upon omission of
the primary antibody (Figure 5C, lower panel). Related to
previous observations of BDNF in circulating platelets (Chacón-
Fernández et al., 2016), we also detected CFP fluorescence
in vessels of non-perfused animals (Figure 5D, upper panel;
Supplementary Video 1) in contrast to perfused animals, where
platelets are expected to be washed out (Figure 5D, lower panel).
Common wiring of nerve and blood vessels has been
suggested (Carmeliet and Tessier-Lavigne, 2005) but its
monitoring has so far been elusive. Our analysis revealed a
dot-like BDNF-IR, co-localized with exon-VI-YFP close to
an exon-IV-CFP positive capillary embedded in the fissura
hippocampalis (FH) (Figure 5E; Supplementary Video 2).
YFP dots represent glutamatergic terminals contacting
Arc-positive dendrites of CA1 neurons (Figures 5F, 6A;
Supplementary Video 1). These dendrites of CA1 neurons are
often embedded within the highly vascularized FH (Soriano
and Frotscher, 1993). At higher magnification, it became
evident that exon-VI-YFP labeled presumptive Schaffer
collateral (SC) terminals contacted postsynaptic spines of
Arc-positive dendrites in the stratum radiatum (SR) (Figure 5G;
Supplementary Video 1). As only a few Arc-positive spines
were contacted by exon-VI-YFP positive dots (Figure 5G,
compare closed and open arrow), we surmise that these may
correspond to activated synapses. Presynaptic expression of
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YFP could be further confirmed by co-localization of YFP
with the presynaptic marker proteins VGLUT1, VGLUT2
and VGLUT3 (Supplementary Figure 5; Somogyi et al., 2004;
Herzog et al., 2006). VGLUT1 and VGLUT3, described in
mossy fiber terminals (Somogyi et al., 2004; Herzog et al.,
2006), were found to be co-localized with YFP in the CA3
region (Supplementary Figures 5A,B). VGLUT2, described in
perforant path terminals contacting dentate gyrus granular cells
(Herzog et al., 2006), was found to be co-localized with YFP in the
stratum moleculare (Supplementary Figure 5C). Interestingly,
YFP also co-localized with VGLUT3 in the glomerular layer of
the olfactory bulb, suggesting exon-VI-YFP to co-localize in
glomerular layer-projecting cholinergic terminals (Case et al.,
2017).
BDNF-positive dots co-localizing with exon-VI-YFP were also
observed close to a nucleus of an endothelial cell (Figure 5H,
magnified from Figure 5B, No. 3), as shown by co-staining with
the p75NGF receptor, an endothelial marker (Xu et al., 2008;
Figure 6B). The characteristic exon-VI-YFP pattern close to
endothelial nuclei was repeatedly found to either overlap with
parvalbumin (PV), a marker of inhibitory neurons (Figure 5I;
Supplementary Video 1), or IBA-1 (ionized calcium-binding
adapter molecule 1), a marker of microglia (Frick et al., 2013;
Figure 5J; Supplementary Video 1).
The BDNF-IR pattern typically seen close to blood vessels
in the SR (Figures 5B, 6C) co-localized with exon-VI-YFP
(Figure 6C, closed arrow) and exon-IV-CFP expressing
presynaptic boutons (Figure 6C, arrowhead), both clearly
overlapping with IBA1-labelled microglia (Figure 6C, open
arrow; Supplementary Video 2). The exon-IV-CFP and
exon-VI-YFP signals may represent SC terminals contacting
microglia. In addition to microglia, the astrocyte specific marker
GFAP (glial fibrillary acidic protein) also co-localized with
exon-VI-YFP in close proximity to blood vessels (Figure 6D;
Supplementary Video 2).
Finally, we observed BDNF-IR in capillary vessels, possibly
within endothelial cells (Figure 5B, No. 5; Figure 6E),
confirming previous observations (Donovan et al., 2000).
Here, clusters of BDNF-IR were seen in zones (Figure 6E) where
desmin positive pericyte processes variably surrounded the
abluminal endothelial wall of an exon-IV-CFP positive blood
vessel encircled by β 1-guanylyl cyclase (GC)-positive smooth
muscle cells (Figure 6E, red; Supplementary Video 2).
These findings demonstrated several key points. First,
wherever we detect exon-IV-CFP or exon-VI-YFP in the
hippocampal path we also detect BDNF. Second, sites where
BDNF is detected correspond to cell types previously shown to
express BDNF. Third exon-IV-CFP and exon-VI-YFP containing
splice variants are translated in non-overlapping locations on
the cellular and subcellular level. Exon-IV-CFP is targeted
to the somata of pyramidal, granule, or microglial cells,
while exon-VI-YFP is detected in terminals of the tri-synaptic
pathway as well as in the end-feet of microglia or astrocytes.
Finally, BDNF in circulating blood is translated from exon-
IV containing transcripts while BDNF in endothelial cells is
probably translated neither from exon-IV nor from exon-VI
containing transcripts.
In conclusion, the BLEV reporter mouse line allows
observation of differences in exon-IV and -VI specific BDNF
expression in distinct neuronal, glial, and vascular cells using
high-resolution fluorescence microscopy.
Activity-Dependent Up-Regulation of
Exon-IV-CFP and Exon-VI-YFP Expression
in BLEV Reporter Mice After Injection With
Kainic Acid
To investigate whether the BLEV reporter mouse line is suitable
to study activity-dependent alterations of Bdnf exon-IV and Bdnf
exon-VI usage in vivo, we validated CFP and YFP expression
following the injection of kainic acid (KA) into homozygous
BLEV reporter mice. KA has been shown to increase BDNF
expression in the hippocampus by agonizing glutamate receptors
(Zafra et al., 1990; Sathanoori et al., 2004; Chiaruttini et al.,
2008) and to activate translation of exon-IV and -VI containing
Bdnf mRNA (Metsis et al., 1993; Tao et al., 1998; Pattabiraman
et al., 2005; Aid et al., 2007; Chiaruttini et al., 2008). Two hours
following intra-peritoneal injection of KA (12 mg/kg), significant
up-regulation of CFP and YFP protein was observed in the
hippocampus in comparison to vehicle-treated animals using
Western blot (Figure 7A).
We next focused on dentate mossy fiber boutons contacting
hippocampal CA3 pyramidal neurons (Figure 7B), where
activity-dependent expression of BDNF was previously described
(Danzer and McNamara, 2004; Danzer et al., 2008; Dieni et al.,
2012). Brain slices of vehicle- and KA-treated homozygous BLEV
mice were co-labeled with antibodies against the cytoskeletal
activity-regulated gene Arc, a protein essential for BDNF-
dependent consolidation of LTP (Soulé et al., 2006; Messaoudi
et al., 2007; Nair et al., 2017). Low power examination of
deconvoluted high-resolution fluorescence stacks revealed a
strong up-regulation of Bdnf exon-VI (YFP) fluorescence in KA-
treated animals in mossy fiber projection fields of CA3 pyramidal
neurons (Figure 7C), suggesting a KA-induced recruitment of
Bdnf exon-VI derived BDNF in perforant path dendrites. We
also co-stained sections with parvalbumin (PV) antibodies,
a marker for fast inhibitory circuits suggested to be shaped
by BDNF (Yamada and Nabeshima, 2003; Messaoudi et al.,
2007; Minichiello, 2009; Waterhouse et al., 2012). Low power
examination of deconvoluted high-resolution fluorescence stacks
revealed an upregulation of Bdnf exon-IV (CFP) at the level
of CA3 pyramidal neurons which correlated with elevated PV
levels in dendritic pre-synaptic terminals surrounding pyramidal
neurons in a perisomatic distribution (Klausberger et al., 2003;
Somogyi et al., 2014; Figure 7E, CFP: closed arrow, PV: open
arrows). Quantification of the integrated density of YFP and
CFP in the CA3 region approved a significant increase after KA
injection (Figures 7D,F). The quantitative change of YFP and
CFP expression in the hippocampus shown by Western blot
(Figure 7A, right panel), together with the parallel qualitative
and quantitative change in YFP and CFP expression in the CA3
regions (Figures 7C–F), suggest that BLEV reporter mice are
suitable to detect activity-dependent exon-specific changes under
healthy and pathological conditions.
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FIGURE 5 | Co-localization of anti-BDNF antibody with Bdnf exon-IV-CFP and Bdnf exon-VI-YFP in the dentate gyrus (DG, A) and the CA1 region (B–J) (see
Supplementary Video 1). (A) Top panel: schematic view of the granule cell layer (GCL) and the stratum moleculare (SM) of the DG. Low-power examination depicts
BDNF-IR within the GCL of the DG (boxed area in sketch). No labeling was seen when anti-BDNF was omitted. Bottom panel: high-power examination from boxed
area shows BDNF to co-localize with a few CFP-positive dots (arrows) but not with YFP-positive dots. Scale bars: 100µm. (B) BDNF-IR in 5 different characteristic
regions at the level of the stratum radiatum (SR) co-localized with Bdnf exon-VI-YFP and Bdnf exon-IV-CFP, see also Supplementary Figure 4. Scale bars: 100µm.
(C) BDNF-IR in blood vessel (arrows) co-localized with Bdnf exon-IV-CFP but not with Bdnf exon-VI-YFP. No BDNF-IR is observed when BDNF antibody is omitted
(Continued)
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FIGURE 5 | (lower panel). Corresponds to area 1 and 5 in (B). Scale bars: 20µm. (D) Bdnf exon-IV-CFP labeling in blood vessels (arrows) of non-perfused BLEV
mice (upper panel) was lost when animals were perfused (lower panel). Scale bars: 20µm. (E) Schematic overview of the SR in the CA1 region. BDNF-IR co-localized
with Bdnf exon-VI-YFP close to a Bdnf exon-IV-CFP positive capillary in the fissura hippocampalis (FH). Corresponds to 3 and 4 in (B). Scale bar: 10µm. (F)
YFP-positive contacts (closed arrows, see also Supplementary Figure 5) on glutamatergic, Arc-positive dendrites (open arrows) of CA1 neurons embedded within
the highly vascularized FH (arrowheads). Scale bar: 20µm. (G) High-power examination of potential Schaffer collateral (SC) terminals labeled with Bdnf exon-VI-YFP
and contacting postsynaptic Arc-positive spines in the SR (compare open and closed arrows). Scale bar: 5µm. (H) BDNF-IR co-localized with Bdnf
exon-VI-YFP-positive puncta on Bdnf exon-IV-CFP-positive capillaries (CFP not shown). Corresponds to 2 in (B). Scale bar: 10µm. (I) Bdnf exon-VI-YFP-positive
puncta close to an endothelial nucleus (asterisk) overlapping with parvalbumin (PV)-positive interneuron dendrites (arrows). Corresponds to 2 in (B). Scale bar: 10µm.
(J) Bdnf exon-VI-YFP-positive puncta close to an endothelial nucleus overlapping with the microglia marker IBA-1 (arrows). Corresponds to 3 and 4 in (B). Scale bar:
20µm. GC, granular cell; IN, inhibitory interneuron; PC, pyramidal cell; PP, perforant path; SP, stratum pyramidale.
FIGURE 6 | Co-localization of anti-BDNF with Bdnf exon-IV-CFP and Bdnf exon-VI-YFP in the stratum radiatum (SR) and the vasculature of the fissura hippocampalis
(FH) (see Supplementary Video 2). (A) Schematic overview of the stratum radiatum (SR) region of the hippocampal formation. Arc-positive (red) pyramidal cell (PC)
dendrites contact the vascularized fissura hippocampalis (FH) embedded within a Bdnf exon-IV-CFP-positive capillary bed (left). BDNF immunoreactivity (red)
co-localizes with Bdnf exon-VI-YFP puncta within this region covering a Bdnf exon-IV-CFP-positive blood vessel (middle). In another view of the FH region, the Bdnf
exon-VI-YFP puncta contacting Arc-positive dendrites deeply entering the basal membrane of a Bdnf exon-IV-CFP-positive blood vessel is shown (right). Scale bars:
10µm. SP, stratum pyramidale. (B) Bdnf exon-VI-YFP contacting p75NGF receptor-positive (red) endothelia cells of a Bdnf exon-IV-CFP-positive blood vessel. Nuclei
are stained in dark blue with DAPI. Scale bars: 10µm. (C) The characteristic BDNF immunoreactivity pattern (red, dotted circles) seen in the SR region close to blood
vessels outlined with Bdnf exon-IV-CFP. Bdnf exon-VI-YFP-positive labeling (closed arrows) is observed close to an IBA-1-positive (red) microglia soma (open arrows)
that itself targets Bdnf exon-IV-CFP at the microglia pole (closed arrowhead). Scale bars: 10µm. (D) Bdnf exon-VI-YFP-positive pattern (closed arrow) observed in
overlap with glial fibrillary acidic protein (GFAP)-labeled astrocyte endfeets close to a Bdnf exon-IV-CFP-positive blood vessel. Scale bars: 10µm. (E) BDNF-IR (red,
arrows) in endothelial cells in a pattern resembling localization of desmin (green, arrows), a marker of pericytes. Pericyte processes embrace the abluminal
endothelium wall of an exon-IV-CFP-positive blood vessel encircled by β1-guanylyl cyclase (GC)-positive (red) smooth muscle cells. Scale bars: 10µm.
DISCUSSION
The present study proposes the BLEV system as a novel tool
for monitoring BDNF expression based on the localization of
mRNA containing the activity-dependent exons-IV and -VI of
cellular and sub-cellular levels in vitro and in vivo through cyan
fluorescent protein (CFP) and yellow fluorescent protein (YFP).
We introduce the BLEV construct and mouse line as a tool to
(i) analyze promoter activation or targeting characteristics of
Bdnf exon-IV and -VI splice-variants in vitro; (ii) analyze cell
specific differences in Bdnf exon-IV and -VI transcript usage
in neuronal and non-neuronal cells; and (iii) detect activity-
dependent and cell-specific BDNF splice-variant usage under
healthy and pathological conditions in vivo.
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FIGURE 7 | Induction of CFP and YFP expression by kainic acid treatment (KA). (A) Western blot analysis of hippocampal tissue lysates from animals injected with
vehicle or KA. Left panel: representative Western blot against CFP (top) and YFP (bottom). Right panel: densitometric quantification shows significant up-regulation of
CFP and YFP expression after KA treatment. Data represented as mean ± SEM normalized to vehicle treated controls, n = 3–4 animals/group (CFP: 1-sided
Student’s t-test: t = 6.25 DF = 4 p = 0.002; n = 3 animals/group; YFP: 1-sided Student’s t-test: t = 1.99 DF = 6 p = 0.04; n = 4 animals/group). For original blot see
Supplementary Figure 6C. (B) Schematic overview of the hippocampal CA3 region depicting the assumed locations of altered CFP, YFP and Parvalbumin (PV)
expression. (C) CFP and YFP fluorescence in brain slices of vehicle- and KA-treated animals co-labeled with the cytoskeletal activity-regulated gene Arc. Clear
upregulation of Arc (red) mainly in the SP and YFP mainly in the SL can be seen in the hippocampal CA3 region of KA-treated animals in comparison to vehicle-treated
mice. Scale bars: 100µm. (D) Quantification of the integrated density of YFP which is increased after KA injection (YFP: 1-sided Student’s t-test: t = 4.14 DF = 3 p =
0.0128; n = 3 animals/group). (E) An increase in perisomatic CFP (closed arrows) and PV (red, open arrows) signals can be seen in the SP of the hippocampal CA3
region in KA-treated animals in contrast to vehicle-treated mice. Scale bars = 10µm. (F) Quantification of the integrated density of CFP which is increased after KA
injection (CFP: 1-sided Student’s t-test: t = 2.32 DF = 4 p = 0.0405; n = 2–3 animals/group). SL, stratum lucidium; SP, stratum pyramidale; SO, stratum oriens; PC,
pyramidal cell; PP, perforant path; IN, interneuron.
BLEV Mice as a Tool to Investigate
Promoter Activation Patterns of BDNF
Analysis of the gene-structure of BDNF reveals the presence
of nine exons where the eight upstream exons (I-VIII) are
alternatively spliced to the ninth exon (IX), corresponding to the
only exon encoding the BDNF protein (Timmusk et al., 1993; Aid
et al., 2007; Figure 3A). The functions of the eight untranslated
Bdnf exons (I-VIII) each containing a different promoter region
is still unclear (Aid et al., 2007). Several studies investigated
the different Bdnf exons and their activity-dependent activation
(Timmusk et al., 1993; Lauterborn et al., 1996; Shieh et al., 1998;
Takeuchi et al., 2000, 2002; Zha et al., 2001; Fang et al., 2003;
Sathanoori et al., 2004; Sakata et al., 2009). Based on these studies,
it was suggested that these promoters show a spatially distinct
expression pattern and are regulated in a stimulus- and activity-
dependent manner (Timmusk et al., 1993; Aid et al., 2007).
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To our knowledge, however, BDNF expression initiated from
the untranslated Bdnf exons-IV and -VI containing transcripts
has never been addressed in parallel in vivo. Therefore, cell-
specific differences in exon-IV and -VI promoter activation in the
mature system in response to external stimuli have so far never
been detected under physiological conditions. The observed
transcript specific expression corresponding to either of the
distinct splice-variants or both, detected in a neuroglioblastoma
cell line suggests that the BLEV construct may be useful
to identify subtle and complex promoter activation patterns
(Figure 1). While it is well established that activation from
exon-IV promoter occurs following elevated levels of calcium
(Ca2+) (West et al., 2014), the details under which conditions
this occurs, e.g., through glutamate-induced NMDA receptors,
voltage gated Ca2+ channels (VGCCs) or intracellular Ca2+
stores is still elusive. It is also not understood if neuronal, glial
or vascular cells exhibit differences in second messenger cascades
acting on specific promoter sites (e.g., CaMKII or CaMKIV,
MAP kinase) (West et al., 2001; Takeuchi et al., 2002; Tao et al.,
2002; Chen et al., 2003). While e.g., Bdnf exon-IV in platelets is
suggested to be activated through store-operated Ca2+ channels
(Chacón-Fernández et al., 2016), the mechanism associated with
promoter activation remains elusive. An even greater complexity
is observed regarding the Bdnf exon-VI promoter that is
activated only modestly by neuronal activity (Timmusk et al.,
1993; Aid et al., 2007), but is indirectly activated by neuronal
activity through binding to the AP-1 family transcription factor
site (Tuvikene et al., 2016). Here, BDNF-autoregulatory loops,
acting via its promoters (Bambah-Mukku et al., 2014; Harward
et al., 2016) may also be involved. The BLEV reporter system now
allows investigation of this hypothesis in vitro or in vivo.
Kainic acid (KA), shown to activate glutamate receptors
in hippocampal neurons (Zafra et al., 1992; Sathanoori et al.,
2004; Chiaruttini et al., 2008), not only elevates exon-IV- and
exon-VI- derived BDNF expression in hippocampal tissue but
does so in a cell-specific manner (Figure 7), indicating that
the activity-driven activation of BDNF promoters-IV and -
VI is not impaired by the BLEV construct. This experiment
also anticipates the usage of the BLEV construct to investigate
not only cell specific differences in promoter usage but also
the predicted complex interplay between transmitter-induced
changes in BDNF expression and its reciprocal effects on its
receptor TrkB (Flavell and Greenberg, 2008; Sakata et al., 2009;
Lu et al., 2010). Here the perspective that the BLEV construct
can be viewed using two-photon microscopy (Thaler and Vogel,
2006) following manipulations of promoter activation under
different conditions is most promising.
In this context, the demonstration of differences in
intraneuronal targeting of BDNF transcripts between in
vitro and in vivo conditions observed in the present study is
particularly interesting. Accordingly, Bdnf exon-IV and -VI
were found in primary neuronal cultures to be targeted mainly
to the soma and dendrites, respectively, as described previously
(Chiaruttini et al., 2008; Baj et al., 2011; Vaghi et al., 2014). In
the mature BLEV mouse model a differential intraneuronal
targeting of BDNF transcripts derived from exon-IV-CFP to the
soma and exon-VI-YFP to terminals (Chiaruttini et al., 2008; Baj
et al., 2011; Vaghi et al., 2014) could not only be demonstrated
for projecting neurons but interestingly also for microglia
(Figures 5J, 6C). Importantly, however, and different from
previous suggestions, we did not observe exon-VI-YFP signals
in dendrites of e.g., the CA1 region (Figures 5F,G). Whether
these observations support the previously suggested elusive
anterograde transport of BDNF transcripts and its restricted
presynaptic BDNF release (Dieni et al., 2012) needs further
investigation. Indeed, we cannot entirely exclude that Bdnf
transcripts may be differentially compartmentalized depending
on the type of stimulus and time course, as shown previously
(Chiaruttini et al., 2008).
This observation is of crucial interest since trafficking of exon-
VI derived BDNF to nerve terminals is thought to be disturbed
in animals or humans carrying the BDNFVal66Met allele, causing a
mutation linked to cognitive deficits (Baj et al., 2013; Mallei et al.,
2015).
BLEV Mice as a Tool to Investigate
Cell-Specific and Transcript-Specific
Differences of BDNF Expression
The low abundance of BDNF in the mature CNS currently
hampers investigation of cell-specific BDNF expression
differences in the healthy or diseased mature brain (Dieni et al.,
2012). We have shown that the localization of BDNF via specific
antibodies overlaps with either exon-IV-CFP or exon-VI-YFP
signals in neuronal, glial, or vascular compartments within the
hippocampus (Figure 5). Importantly, the identified BDNF
patterns correspond to previously observed regions of BDNF
expression in neuronal or non-neuronal cells (Dieni et al.,
2012; Chacón-Fernández et al., 2016). Thus our data imply
that for example BDNF translation in the soma of hippocampal
pyramidal cells (Danzer et al., 2008) results from Bdnf exon-
IV splice variants, while BDNF translation in tri-synaptic
hippocampal terminals (Danzer et al., 2008; Dieni et al., 2012)
is generated by Bdnf exon-VI splice variants (Figures 5B, 6;
Supplementary Video 1). In addition, expression of BDNF in
astrocytes or microglia (Snapyan et al., 2009; Parkhurst et al.,
2013), predicted to participate in the recruitment of blood vessels
during complex homeostatic changes in plasticity (Edelmann
et al., 2014, 2017), may be driven by exon-IV in the glial soma
or by exon-VI when released from glial end-feet structures
(Figures 6C,D; Supplementary Video 1). The BLEV reporter
mice may thus provide a new resource to investigate to what
extent the BDNFVal66Met polymorphism, linked to cognitive
deficits, may not only affect trafficking in neuronal (Baj et al.,
2013; Mallei et al., 2015) but possibly also in microglial cells.
Moreover, our results in BLEVmice indicate for the first time that
BDNF is also present in mouse platelets, as previously described
in humans and rats (Chacón-Fernández et al., 2016). How
exon-IV derived BDNF in platelets can communicate through
the blood-brain barrier that is maintained by endothelial tight
junctions, pericytes, or astrocytic end-feet (Marosi and Mattson,
2014) could be part of future studies in BLEV mice. Finally,
BDNF in endothelial cells, identified through co-localization
of BDNF with p75NGFR (for review see: Donovan et al., 2000;
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Marosi and Mattson, 2014), appears to be neither generated by
exon-IV nor by exon-VI promoters (Figures 5B, 6B).
Conclusively, BLEV mice may thus be the first animal model
enabling the parallel monitoring of BDNF expression differences
in neurons, glial cells, and capillaries, including subcellular
targeting in neurons and glial cells.
BLEV Mice as a Tool to Investigate
Stimulus-Driven Cell-Specific and
Transcript-Specific Differences of BDNF in
Healthy and Pathological Conditions in vivo
The analysis of the role that BDNF plays for the nervous system
has until now mainly focused on in vitro studies or BDNF
knock-out mouse models. BDNF knock-out mice die postnatally
(Ernfors et al., 1995) and therefore escape investigations of
BDNF’s roles in the mature system, particularly of those in
response to changes in neuronal activity. However, the presently
existing mouse models have indicated important phenotypic
differences in the absence of BDNF signaling in the mature
system. Accordingly, heterozygous BDNF knock-out animals
show anxiety-like behavior (Chourbaji et al., 2008) or signs of
obesity (Rios et al., 2001; Vanevski and Xu, 2013). Mice with
a point mutation in the BDNF receptor TrkB gene exhibit
progressive hearing loss (Postigo et al., 2002), while mice with
a conditional deletion of BDNF from cortical neurons show a
severe reduction of dendritic contacts (Rauskolb et al., 2010). A
first hint for a crucial role of distinct BDNF transcripts in control
of cortical inhibition, aggressive behavior (Lyons andWest, 2011;
Hill et al., 2016; Maynard et al., 2016), or e.g., in the induction of
depression was obtained in BDNF mouse models in which one
of its promoters had been impaired (Hong et al., 2008; Sakata
et al., 2009). A further indication that intracellular targeting of
BDNF transcript defines e.g., cognitive competence has been
observed in BDNFVal66Met mutants (Mallei et al., 2015). So far,
however, none of these studies can explain why different activity-
dependent BDNF promoters may provide advantages over usage
of a single promoter.
Various studies have confirmed the requirement of
glucocorticoid signaling in selected networks to support
morphological changes at synapses (Cheng et al., 2012; Liston
et al., 2013; Arango-Lievano et al., 2015) and an activity-
dependent process to provide information about the appropriate
context (De Kloet et al., 2014; Jeanneteau and Arango-Lievano,
2016). Indeed, previous hypotheses considered that activity-
dependent BDNF expression provides context-dependent
information for GR-mediated task-evoked plasticity changes
to be associated with memory formation (Jeanneteau and
Arango-Lievano, 2016). Up to now, however, it was not possible
to directly observe activity-driven BDNF transcription. With
the BLEV mouse, we now provide a suitable new tool for this
purpose. In contrast to existing BDNF-GFP reporter mice
(Guillemot et al., 2007), the BLEV model provides the advantage
to allow visualization of different BDNF transcripts following
activity and thereby to specifically monitor stimulus-driven
activation patterns in networks. As a prerequisite to detect
stimulus-driven BDNF transcript changes, we had to assure
that gene replacement within the Bdnf locus did not interfere
with the normal expression of the BDNF protein. BLEV mice
were confirmed to express unchanged levels of BDNF and
showed normal weight, lifespan, fertility, and function of the
audio-vestibular sensory system. This is particularly important
with regard to the crucial role BDNF plays for normal cognitive
function (reviews: Minichiello, 2009; Lu et al., 2014; Leal
et al., 2015), neurogenesis (Kheirbek et al., 2012; Waterhouse
et al., 2012), energy homeostasis and pattern segregation
(for review see: Bramham and Messaoudi, 2005; Rauskolb
et al., 2010; Park and Poo, 2013; Marosi and Mattson, 2014;
Turrigiano, 2014; Bothwell, 2016; Mitre et al., 2017). The lack
of a changed phenotype thus qualifies BLEV reporter mice
as new tool to investigate how expression of exon-IV and
-VI derived BDNF changes after altered input activity in the
different neuronal, glial or vascular cells during modulation
of the aforementioned processes. This includes the use of
BLEV mice for examining potential therapies in various disease
models, where dysregulation of BDNF expression is predicted
to contribute to the pathology, such as depression, epilepsy, or
Alzheimer’s, Huntington’s, and Parkinson’s disease (Bibel and
Barde, 2000; Ginsberg et al., 2017).
As a first attempt to test if BLEV mice enable identification of
activity-dependent adaptations in central networks under healthy
or pathological conditions we shall focus on known plasticity
paradigms in the hippocampus. The hippocampus is the region
with highest levels of BDNF expression (Nawa et al., 1995;
Conner et al., 1997), where it is predicted to play crucial roles
for accentuating behaviorally important sound signals (Kilgard
and Merzenich, 1998; Sadaghiani et al., 2009; Kraus and White-
Schwoch, 2015; Weinberger, 2015). The precise organization
of the peripheral and central auditory system together with
functionally and molecularly established protocols (Rüttiger
et al., 2017) to induce long-lasting plasticity changes related
to memory (for review see: Knipper et al., 2013; Singer et al.,
2013), provides an excellent model to investigate sound-induced
activation patterns of Bdnf transcripts with the help of BLEV
mice.
CONCLUSION
In the present study, a transgenic system for BDNF-live-exon-
visualization (BLEV) has been generated enabling the detection
of activity-dependent BDNF translation from Bdnf exon-IV and
-VI containing transcripts through CFP and YFP fluorescent
proteins, respectively. The present study confirms (i) that
transfection of different cell lines with the BLEV construct
enables the tracking of intraneuronal targeting differences of the
BDNF splice variants; (ii) that insertion of the BLEV construct
into the genomic locus of Bdnf via homologous recombination
resulted in healthy homozygous BLEV reporter mice without
any apparent phenotypic changes and with normal levels of
BDNF expression; (iii) that CFP and YFP fluorescence in BLEV
mice overlaps with BDNF protein expression in neuronal, glial,
and vascular locations; and (iv) that the BLEV construct allows
identification of elevated Bdnf exon-IV-CFP and exon-VI-YFP
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expression levels following glutamate receptor activation in vivo.
BLEV reporter mice can now be used to trace the potential role of
activity-dependent BDNF promoter usage for providing context-
specific information during task-specific memory formation.
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